NICHOLAS GILFUS: Open Payments
NPI 1417311523 · ELBRIDGE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$607 in 27 payments from 16 companies in 2025. Trend: 2023 $614 · 2024 $354 · 2025 $607
Food & beverage: $607
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $102 |
| Corcept Therapeutics | 3 | $78 |
| Astellas Pharma US Inc | 2 | $66 |
| Seqirus USA Inc | 2 | $52 |
| Merck Sharp & Dohme LLC | 2 | $49 |
| Novo Nordisk Inc | 3 | $47 |
| GlaxoSmithKline, LLC. | 1 | $34 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $33 |
| PFIZER INC. | 1 | $23 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
Products named: Korlym, QULIPTA, Veozah, Flucelvax, TRELEGY ELLIPTA, JOURNAVX, UBRELVY, LAGEVRIO.
Industry payments across NY — which companies pay providers there.
